Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

NCT05389423 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

25

Enrollment

NIH

Sponsor class

Conditions

Diffuse Large Cell Lymphoma
Non-Hodgkin Lymphoma
Burkitt Lymphoma
Plasmablastic Lymphoma
B-Cell Neoplasm

Interventions

DRUG: Vincristine
DRUG: Prednisone
DRUG: Doxorubicin
DRUG: Etoposide
DRUG: Pomalidomide
DRUG: Cyclophosphamide
DRUG: Rituximab

Sponsor

National Cancer Institute (NCI)